Amicus Therapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J., Dec. 22, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 12 at 8:00 a.m. PT (11 a.m. ET).
Mr. Crowley will introduce the Company's financial guidance, strategic outlook and anticipated milestones for fiscal year 2012, and intends to provide an update on newly available data from Study 013, an open-label Phase 2 drug-drug interaction study of migalastat HCl co-administered with enzyme replacement therapy (ERT) for Fabry disease.
A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm , and will be archived for 90 days. Participants are encouraged to visit the web site 10 minutes prior to the start of the presentation to register, download and install any necessary software.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program migalastat HCl is in Phase 3 for the treatment of Fabry disease.
About Migalastat HCl
Migalastat HCI is an investigational oral pharmacological chaperone in Phase 3 development for the treatment of Fabry disease being developed in collaboration with GlaxoSmithKline PLC (GSK). Under the terms of the collaboration, GSK has an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl. Amicus and GSK are conducting two Phase 3 global registration studies (Study 011 and Study 012) of migalastat HCl monotherapy, along with a Phase 2 study (Study 013) evaluating migalastat co-adminstered with enzyme replacement therapy (ERT) for the treatment of Fabry disease.
CONTACT: Amicus Therapeutics Sara Pellegrino (609) 662-5044 firstname.lastname@example.orgSource: Amicus Therapeutics, Inc. 2011 GlobeNewswire, Inc.